Cancer Anemia

At present, numerous free radical studies related to many pathologies have been carried out. The amount of these studies is really enormous and many of them are too far from the scope of this book. The main topics of this chapter will be confined to the mechanism of free radical formation and oxidative processes under pathophysiological conditions. We will consider the possible role of free radicals in cardiovascular disorders, cancer, anemias, inflammation, diabetes mellitus, rheumatoid arthritis, and some other diseases. Furthermore, the possibilities of antioxidant and chelating therapies will be discussed. 

Kumar P. Importance of anemia as a prognostic factor in patients with head and neck cancer. Anemia Oncol 2000 3 2 1. 

As - cerebral lesions - pulmonary cancer chronic bronchitis -hemoglobi- nuria hematuria kidney cancer -hepatopor-tal sclerosis liver cancer - anemia leukopenia tachycardia... 

Treatment of diabetes mellitus Leukemia, AIDS, and renal cell carcinoma AIDS, multiple sclerosis, and cancer Anemia and chronic renal failure Cancer treatment Heart attack... 

Aromatic Hydrocarbons. These are the most toxic of the hydrocarbons and inhalation of the vapor can cause acute intoxication. Benzene is particularly toxic and long-term exposure can cause anemia and leukopenia, even with concentrations too low for detection by odor or simple instmments. The currendy acceptable average vapor concentration for benzene is no more than 1 ppm. PolycycHc aromatics are not sufftcientiy volatile to present a threat by inhalation (except from pyrolysis of tobacco), but it is known that certain industrial products, such as coal tar, are rich in polycycHc aromatics and continued exposure of human skin to these products results in cancer. 

Thorotrast (colloidal Th02) was once used as a radiopaque agent in medicine (see Radiopaques). Its injection in a dose of 2.0—15.0 g caused rises in body temperature, nausea, and injury to tissues at the injection site, followed by anemia, leukopenia, and impairment of the reticuloendothehal system. After intravenous adrninistration, thorotrast particles are taken up by reticuloendothehal cells of the fiver and spleen. Thorotrast is virtually not eliminated from the body (91). Between 1947 and 1961, 33 cases of cancer of the fiver, larynx, and bronchi and sarcoma of the kidneys, developing from 6 to 24 years after thorotrast administering, have been described in the literature (92). 

Alachlor zero 0.002 Eye, liver, kidney or spleen problems anemia increased risk of cancer Runoff from herbicide used on row crops... 

Benzene zero 0.005 Anemia decrease in blood platelets increased risk of cancer Discharge from factories leaching from gas storage tanks and landfills... 

Capecitabine is used for the treatment of colorectal and breast cancers. It is contraindicated in patients with known hypersensitivity to capecitabine or any of its components or to 5-fluorouracil and in patients with known dihydropyrimidine dehydrogenase (DPD) deficiency. The use of capecitabine is restricted in patients with severe renal impairment. The drag can induce diarrhea, sometimes severe. Other side effects include anemia, hand-foot syndrome, hyperbilirubinemia, nausea, stomatitis, pyrexia, edema, constipation, dyspnea, neutropenia, back pain, and headache. Cardiotoxicity has been observed with capecitabine. A clinically important drag interaction between capecitabine and warfarin has been demonstrated. Care should be exercised when the drag is co-administered with CYP2X9 substrates. 

Thus, our attention should shift from the concern of potential adverse effects to the health benefits imparted by hormonal contraceptives. The use of oral contraceptives for at least 12 months reduces the risk of developing endometrial cancer by 50%. Furthermore, the risk of epithelial ovarian cancer in users of oral contraceptives is reduced by 40% compared with that on nonusers. This kind of protection is already seen after as little as 3-6 months of use. Oral contraceptives also decrease the incidence of ovarian cysts and fibrocystic breast disease. They reduce menstrual blood loss and thus the incidence of iron-deficiency anemia. A decreased incidence of pelvic inflammatory disease and ectopic pregnancies has been reported as well as an ameliorating effect on the clinical course of endometriosis. 

Erythropoietin (Eprex ) is physiologically produced in the kidney and regulates proliferation of committed progenitors of red blood cells. It is used to substitute erythropoietin in severe anemias due to end stage renal disease or treatment of cancer with cytostatic agents. Side effects include hypertension and increased risk of thrombosis. 

Erythropoietin is a growth factor produced by interstitial cells of the kidney in response to hypoxia. Erythropoietin stimulates haematopoiesis in the bone marrow. Recombinant human erythropoietin is used to treat anemias, e.g. anemia caused by chronic renal failure and anemia in AIDS and cancer patients. 

The recombinant hematopoietic growth factors have had a significant impact on the treatment of cancer, including prevention of serious infections and anemia. 

The uses of the various anabolic steroids include management of anemia of renal insufficiency, control of metastatic breast cancer in women, and promotion of weight gain in those with weight loss after surgery, trauma, or infections. Stanozolol is used prophylactically... 

Taking the contraceptive hormones provides health benefits not related to contraception, such as regulating the menstrual cycle and decreased blood loss, and incidence of iron deficiency anemia, and dysmenorrhea Health benefits related to the inhibition of ovulation include a decrease in ovarian cysts and ectopic pregnancies. hi addition, there is a decrease in fibrocyctic breast disease, acute pelvic inflammatory disease endometrial cancer, ovarian cancer, maintenance of bone density, and symptoms related to endometriosis in women taking contraceptive hormones. Newer combination contraceptives such as norgestimate and ethinyl estradiol... 

Knowledge of the biochemistry of the porphyrins and of heme is basic to understanding the varied functions of hemoproteins (see below) in the body. The porphyrias are a group of diseases caused by abnormalities in the pathway of biosynthesis of the various porphyrins. Although porphyrias are not very prevalent, physicians must be aware of them. A much more prevalent clinical condition is jaundice, due to elevation of bilirubin in the plasma. This elevation is due to overproduction of bilirubin or to failure of its excretion and is seen in numerous diseases ranging from hemolytic anemias to viral hepatitis and to cancer of the pancreas. 

The commonest causes of obstructive (posthepatic) jaundice are cancer of the head of the pancreas and a gallstone lodged in the common bile duct. The presence of bilirubin in the urine is sometimes referred to as choluria—therefore, hepatitis and obstruction of the common bile duct cause choluric Jaundice, whereas the Jaundice of hemolytic anemia is referred to as acholuric. The laboratory results in patients with hepatitis are variable, depending on the extent of damage to parenchymal cells and the extent of micro-obstruction to bile ductules. Serum levels of ALT and AST are usually markedly elevated in hepatitis, whereas serum levels of alkaline phosphatase are elevated in obstructive liver disease. 

In patients with ataxia-telangiectasia, an autosomal recessive disease in humans resulting in the development of cerebellar ataxia and lymphoreticular neoplasms, there appears to exist an increased sensitivity to damage by x-ray. Patients with Fanconi s anemia, an autosomal recessive anemia characterized also by an increased frequency of cancer and by chromosomal instability, probably have defective repair of cross-linking damage. 

Complete blood count anemia may be due to cancer or another systemic disorder accompanied by constipation. 

The following "red flag" or alarm features are not associated with IBS and may indicate inflammatory bowel disease, cancer, or other disorders fever, weight loss, bleeding, and anemia, which may be accompanied by persistent severe pain. 

Evaluate the proper use of epoetin and darbepoetin in anemia patients with cancer and kidney disease. 

Therapy with epoetin or darbepoetin can increase hemoglobin, decrease transfusion requirements, and improve quality of life in cancer and kidney disease patients with anemia. 

A decrease in erythrocyte production can be multifactorial. A deficiency in nutrients (such as iron, vitamin B12, and folic acid) is a common cause that often is easily treatable. In addition, patients with cancer and CKD are at risk for developing a hypoproductive anemia. Furthermore, patients with chronic immune-related diseases (such as rheumatoid arthritis and systemic lupus erythematosus) can develop anemia as a complication of their disease. Anemia related to these chronic inflammatory conditions is typically termed anemia of chronic disease. 

Comorbid conditions can increase the risk of anemia substantially. Anemia is especially common in cancer patients receiving chemotherapy and patients with chronic kidney disease (CKD). The incidence of anemia in cancer patients varies based on tumor type and the level of myelo-suppression the chemotherapy regimen causes. For instance, serious anemia [hemoglobin 7.9 g/dL or less (79 g/L or 4.9 mmol/L)] occurs in at least 75% of patients who receive a common chemotherapy regimen for lymphoma, but serious anemia may occur in only approximately 10% of patients who receive common chemotherapy regimens for... 

Anemia of chronic disease is a term given those with underlying conditions that contribute to or cause anemia in a patient. These chronic diseases can include cancer, chronic... 

The National Comprehensive Cancer Network (NCCN) recommends an anemia work-up for patients with hemoglobin of less than 11 g/dL (110 g/L or 6.8 mmol/L). Patients who are symptomatic or asymptomatic with significant risk factors (e.g., extensive transfusion history, myelosuppressive chemotherapy, etc) may qualify for treatment with erythropoietic agents such as epoetin-alfa or darbepoetin. Data do not support the use of one agent over another they are both equally effective in treating this type of anemia.12 Table 63-4 provides dosing recommendations for chemotherapy-related anemia. 

---